Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 805 results for "eisai"

Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan
Sys-Con Media

Eisai seeks Japanese, US & EU regulatory nods for anticancer a...

Eisai Co., Ltd., engaged in manufacturing and selling pharmaceutical products worldwide, has submitted applications to regulatory authorities in Japan, the United States and Europe (MHLW, FDA and EMA respectively) seeking an additional indication ... PharmaBiz, 4 hours ago
Eisai submits regulatory applications for eribulin in the US, EU and Japan European Pharmaceutical Review, 22 hours ago
[x]  
Sys-Con Media

Eisai, Halozyme Anounce Collaboration to Investigate Eribulin and Pegph20 in Advanced Breast Cancer

Eisai Co., Ltd. (OTC: ESALY) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that they have signed a clinical collaboration agreement to evaluate Eisai'santicancer agent eribulin mesylate (brand name: Halaven, "eribulin") in ...
 Benzinga.com1 day ago Eisai Inc. (ESALF.PK) And Halozyme (HALO) Sign Collaboration Agreement To Investigate Eribulin And PEGPH20 In Metastatic Breast Cancer 7/31/2015  ClinicSpace18 hours ago Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer  News-Medical.Net23 hours ago Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer  Sys-Con Media1 day ago
[x]  

Eisai's (ESALY) Q1 2016 Results - Earnings Call Transcript

Eisai Co., Ltd. (ESALY) Q1 2016 Earnings Conference Call July 31, 2015 3:15 AM ET Executives Ryohei Yanagi - Chief Financial Officer, Chief IR Officer Hideki Hayashi - Corporate Strategy and Planning; Chief Information Officer, CEO ...
 TeleTrader.com14 hours ago

Eisai reicht in den USA, Japan und der EU einen Antrag für eine neue Indikation für Halaven® (Eribulin) bei Weichteilsarkomen ein

/PRNewswire/ -- NUR FÜR MEDIEN AUS EMEA-LÄNDERN. NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ//ÖSTERREICH/DEN USA JOURNALISTEN Eine Typ 2 Variation zur Beantragung der Erweiterung der Indikation von Halaven ® (Eribulin) wurde in der ...
 PR Newswire1 day ago

Halaven® (éribuline) : Eisai dépose des demandes d'enregistrement simultanément aux Etats Unis, au Japon et UE pour le traitement du sarcome des tissus mous

/PRNewswire/ -- Une demande de variation de type II a ete soumise en union europeenne, pour l'extension d'indication d' Halaven ® (eribulin) dans le traitement des patients atteints de sarcome des tissus mous, non resecable ayant recu au ...
 PR Newswire1 day ago

Eisai presenterà la richiesta di autorizzazione all'immissione in commercio di Halaven® (Eribulina) per il sarcoma dei tessuti molli negli Stati Uniti e in Giappone

/PRNewswire/ -- DESTINATO ESCLUSIVAMENTE AI MEDIA DELL'AREA EMEA: NON DESTINATO AI GIORNALISTI DI SVIZZERA/ AUSTRIA /STATI UNITI In data odierna verrà presentata la richiesta di autorizzazione all'immissione in commercio nell'Unione europea ...
 PR Newswire1 day ago

Eisai solicita autorización en la Unión Europea, Estados Unidos y Japón para una nueva indicación de Halaven® (eribulina) en sarcoma de tejidos blandos

/PRNewswire/ -- SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA: NO PARA LOS MEDIOS SUIZOS/AUSTRÍACOS/ESTADOUNIDENSES Se ha presentado una variación de tipo II ante la Unión Europea para ampliar la indicación de Halaven ® (eribulina) al ...
 PR Newswire1 day ago

Eisai to launch Eidia's Stacia Cleia Pivka-II Eisai in Japan

Eisai Co., Ltd. and its diagnostics subsidiary Eidia Co., Ltd. have announced that Eidia will launch Stacia Cleia Pivka-II Eisai in Japan. The new diagnostic kit is specially designed to measure PIVKA-II, a tumor marker for hepatocellular carcinoma ...
 Individual.com4 days ago
Pharmaceutical Business Review

JCR Pharmaceuticals and Eisai sign feasibility study agreement

JCR Pharmaceuticals Co., Ltd., a biopharmaceutical company, and Eisai Co., Ltd. have signed a feasibility study agreement, under which they will examine the possibility of applying JCR's proprietary blood-brain-barrier, or BBB, penetration ...
 Individual.com1 week ago Eisai, JCR to discover new CNS treatments using BBB penetration technology  Pharmaceutical Business Review1 week ago JCR and Eisai conclude feasibility study agreement on application of blood-brain-barrier penetration technology to discover new treatments  PipelineReview1 week ago JCR, Eisai conclude feasibility study pact on application of blood-brain-barrier penetration technology to discover new treatments  PharmaBiz1 week ago

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Eisai Co. said its new thyroid cancer drug is reaching patients faster than originally planned, months after regulators in its two biggest markets approved the treatment. More patients than had been initially targeted are receiving Lenvima at ...
 Bloomberg1 week ago Eisai drug extends survival in patients with rare cancers  Reuters2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less